Comparative Pharmacology
Head-to-head clinical analysis: PROPOXYPHENE COMPOUND 65 versus WYGESIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROPOXYPHENE COMPOUND 65 versus WYGESIC.
PROPOXYPHENE COMPOUND 65 vs WYGESIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propoxyphene is an opioid analgesic that binds to mu-opioid receptors in the central nervous system, resulting in inhibition of ascending pain pathways and alteration of pain perception. Acetaminophen component inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis.
WYGESIC (ibuprofen and hydrocodone) combines a nonsteroidal anti-inflammatory drug (ibuprofen) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, and a narcotic analgesic (hydrocodone) that acts as a mu-opioid receptor agonist.
Adults: 1 capsule (65 mg propoxyphene HCl + 650 mg acetaminophen) orally every 4 hours as needed; maximum 6 capsules per day.
1-2 tablets (paracetamol 325 mg / tramadol 37.5 mg) orally every 4-6 hours as needed for pain, not to exceed 8 tablets per day.
None Documented
None Documented
The terminal elimination half-life of propoxyphene is approximately 8-24 hours (mean 12 hours) in healthy adults. The half-life of its active metabolite, norpropoxyphene, is 30-36 hours, leading to prolonged effects and potential accumulation with repeated dosing, especially in renal impairment.
3–4 hours in healthy adults; prolonged to 5–6 hours in moderate renal impairment (CrCl 30–50 mL/min) and >11 hours in severe renal impairment (CrCl <30 mL/min).
Renal excretion of propoxyphene and its metabolites accounts for approximately 70-90% of an administered dose, with less than 5% excreted as unchanged drug. The remainder is eliminated via bile and feces. Minor amounts are excreted in breast milk.
Primarily renal: 90% as unchanged drug and glucuronide conjugate; <5% fecal.
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination